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Abstract
Background: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation
chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined. The aim of this study was
to evaluate the efficacy and toxicity of CCT.
Methods: The characteristics of LA-NSCLC patients treated with curative concurrent CRT from 2001 to 2010 were
retrospectively reviewed.
Results: Among 203 patients, 113 (55.7 %) patients received CCT. The median number of delivered CCT was 3 and
89.4 % patients completed ≥2 cycles. The OS was significantly better for patients in the CCT group compared with that
in the non-CCT group (median OS, 27 months vs. 16 months; 5-year OS, 30.4 % vs. 22.5 %; p = 0.012). The median PFS
were 12 months in the CCT group and 9 months in the non-CCT group (p = 0.291). The survival advantages of CCT
were significant for males (HR: 0.63; 95 % CI, 0.44 − 0.90), patients with age < 60 years (HR: 0.63; 95 % CI, 0.42 − 0.95),
non-squamous histology (HR: 0.44; 95 % CI, 0.25 − 0.76), pretreatment KPS≥ 80 (HR: 0.67; 95 % CI, 0.48 − 0.93), stage IIIb
(HR: 0.64; 95 % CI, 0.43 − 0.95), stable disease (HR: 0.31; 95 % CI, 0.14 − 0.65) and radiotherapy dose≥ 60 Gy (HR: 0.69;
95 % CI, 0.48 − 1.00). There was no significant difference between the CCT group and the non-CCT group regarding
treatment-related toxicities.
Conclusions: CCT might further prolong survival compared with CRT alone for LA-NSCLC without increasing treatment-
related toxicities, especially for males, patients with age < 60 years, non-squamous histology, pretreatment KPS≥ 80,
stage IIIb, stable disease and radiotherapy dose≥ 60 Gy. Large size prospective investigations that incorporate patient
characteristics and treatment response are warranted to validate our findings.
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Background
Lung cancer remains the leading cause of cancer-
related deaths worldwide [1]. Non-small-cell lung can-
cer (NSCLC) accounts for 80 % of all lung cancer cases
and approximately 40 % of patients with NSCLC present
with locally advanced non-small-cell lung cancer (LA-
NSCLC) at diagnosis [2]. The standard-of-care treatment
for LA-NSCLC is concurrent platinum-based chemother-
apy and thoracic radiotherapy [3–5], which yields superior
survival compared with either radiotherapy alone or
sequential chemoradiotherapy. However, the outcome of
LA-NSCLC treated with concurrent chemoradiotherapy
(CRT) remains disappointing, with a median survival of
12–23.2 months [6, 7].
To improve survival, numerous studies have focused
on exploring the feasibility and efficacy of consolidation
chemotherapy (CCT) following concurrent CRT with
discordant results. A phase II study of the Southwest
Oncology Group (SWOG) 9504 [8] treated patients with
concurrent CRT followed by consolidation docetaxel and
achieved a promising median survival of 26 months sug-
gesting a possible benefit of CCT. However, the Hoosier
Oncology Group (HOG) [6], who published the only full
article on a randomized phase III trial thus far, failed to
replicate the encouraging outcome of SWOG 9504 by
randomly delivering either docetaxel or observation after
CRT. A recent pooled analysis [2] of 45 studies showed
that CCT provided no survival benefit for LA-NSCLC
patients. However, a subgroup analysis demonstrated
that Asian populations (mostly from Japan and Korea)
tended to benefit from CCT, although this benefit did
not meet statistical significance (HR = 0.84; 95 % CI,
0.68-1.04; p = 0.105). Given the lack of substantial evi-
dence from randomized phase III clinical trials, the de-
finitive role of CCT in LA-NSCLC is unknown,
especially in the Asian population. Therefore, our study
attempted to evaluate the efficacy and toxicity of CCT
after concurrent CRT at our institution.
Methods
Ethics statement
This retrospective study was approved by the ethics com-
mittee of the Cancer Hospital and Institute of Chinese
Academy of Medical Sciences & Peking Union Medical
College. Informed consent was exempted by the board
due to the retrospective nature of this research. Patient re-
cords were anonymized and de-identified prior to analysis.
Eligibility
We retrospectively reviewed the clinical records of LA-
NSCLC patients treated with concurrent CRT as an ini-
tial treatment at out institution between January 2001
and December 2010. The criteria for inclusion were de-
fined as follows: (1) histologically or cytologically proven
NSCLC; (2) clinically diagnosed as stage III disease
according to the American Joint Committee on Cancer
(AJCC) 2009 staging system; (3) treated with curative
thoracic radiotherapy of no less than 50 Gy using intensity
modulated radiotherapy (IMRT) or three-dimensional
conformal radiotherapy (3D-CRT) with concurrent plat-
inum doublet chemotherapy; (4) treatment responses eval-
uated 1 month after the completion of concurrent CRT in
accordance with the Response Evaluation Criteria for
Solid Tumors (RECIST) version 1.1 as complete response
(CR), partial response (PR), and stable disease (SD).
Evaluation and follow-up
Complete blood cell counts (CBCs) and blood chemistry
examinations were repeated once per week during the
treatment period. The follow-up evaluations consisted of
a physical examination, CBC, serum biochemistry, tumor
marker, thoracic computed tomography (CT) scans, abdo-
men B-ultrasound examination, and other necessary im-
aging examinations as clinically indicated at intervals of
3 months for the first year, then every 6 months for the
following 2 years, and annually thereafter. Local recur-
rence was defined as primary tumor recurrence, and
regional recurrence was defined as recurrence in the
mediastinum, hilum and supraclavicular fossa. Other sites
of recurrence, including contralateral lung and metastatic
lymph nodes in the neck or axilla, were defined as distant
metastasis. Disease progression was determined based on
a radiologic examination, histologic examination, or both.
Treatment toxicities were graded according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0.
Data analysis
Overall survival (OS) was defined from the beginning of
concurrent CRT to the time of death due to any cause or
last follow-up. Cancer specific survival (CSS) was defined
from the beginning of concurrent CRT to the time of
death due to lung cancer or last follow-up. Progression-
free survival (PFS) was defined from the beginning of con-
current CRT to the time of tumor progression or last
follow-up. Local regional progression-free survival
(LRPFS) was defined from the beginning of concurrent
CRT to the time of local regional progression or last
follow-up. Distant metastasis-free survival (DMFS) was
defined from the beginning of concurrent CRT to the time
of appearance of metastatic disease or last follow-up. Sur-
vival analysis was performed using the Kaplan-Meier
method and log-rank test. Univariate and multivariate
analyses by use of a Cox-proportional hazards model were
performed to evaluate potential prognostic factors for OS
and PFS. Variables with p < 0.3 in univariate analyses were
entered into multivariate analyses. The Pearson χ2 test
was used to compare the baseline characteristics and
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incidence of specific toxicities between treatment groups.
Cox proportional hazards models, stratified by age, sex,
histology, pretreatment Karnofsky performance score
(KPS), stage, treatment response and radiotherapy dose
were used to estimate HRs and 95 % confidence intervals
(CIs) and test for significance for OS. A statistically signifi-
cant difference was defined as p < 0.05. All data were proc-
essed with SPSS version 19.0.
Results
Patient characteristics
This retrospective study identified 261 consecutive LA-
NSCLC patients who received concurrent chemotherapy
and curative thoracic radiotherapy with a radiation
dose ≥ 50 Gy at our institution between January 2001
and December 2010. We excluded 17 patients whose re-
sponse assessments were unavailable, 13 patients who
experienced disease progression within a month after
concurrent CRT, 18 patients whose concurrent chemo-
therapy did not consist of platinum doublet regimens
and 10 patients who were treated with conventional
two-dimensional radiotherapy; thus, a total of 203 pa-
tients were available for analysis. The characteristics of
the 203 patients are presented in Table 1. The median
follow-up time was 23 months (range, 2–130 months)
for the entire study population and 58.5 months (range,
10–130 months) for censored patients. The median age
of the patients was 56 years (range, 31–73 years). The
majority of patients were male (83.7 %) and younger than
60 years old (64 %) with no significant (<5 %) weight loss
(82 %) and a smoking index > 400 (60.6 %). 94.6 % of pa-
tients had a pretreatment KPS ≥ 80, and 66.5 % of patients
presented with stage IIIb disease. Most patients had nor-
mal hemoglobin (95.6 %) and carcinoembryonic antigen
(CEA) (67.1 %) levels at diagnosis. The most common
histology subtype was squamous cell carcinoma (SCC)
(65.5 %). Only 26.1 % of patients had positron emission
tomography (PET) scan staging.
Of all 203 patients, 161 (79.3 %) were treated with
IMRT and 42 (20.7 %) were treated with 3D-CRT. The
radiation area only included the involved fields. The me-
dian radiation dose was 60 Gy in 30 fractions (range,
50–74 Gy in 25–37 fractions). For the concurrent
chemotherapy regimen, 99 (48.8 %) patients were ad-
ministered EP (etoposide plus cisplatin), 87 (42.8 %) pa-
tients received PC (paclitaxel plus carboplatin) and 17
(8.4 %) patients were treated with other platinum-
doublet regimens. The responses of CR, PR, and SD were
observed in 5 (2.5 %) patients, 161 (79.3 %) patients and
37 (18.2 %) patients, respectively. After concurrent CRT,
113 (55.7 %) patients received CCT, including 88 patients
with platinum-based doublet chemotherapy regimens, and
25 patients with single-agent regimens. Among 113 pa-
tients who received CCT, the median number of delivered
Table 1 Patient characteristics
Characteristic Non-CCT (%) CCT (%) p-value
Gender
Male 83 (92.2) 87 (77.0) 0.003
Female 7 (7.8) 26 (23.0)
Age 0.005
< 60 years 48 (53.3) 82 (72.6)
≥ 60 years 42 (46.7) 31 (27.4)
Weight loss 0.941
< 5 % 74 (82.2) 90 (81.8)
≥ 5 % 16 (17.8) 20 (18.2)
Smoking indexa 0.031
≤ 400 28 (31.1) 52 (46.0)
> 400 62 (68.9) 61 (54.0)
Pretreatment hemoglobin 0.306
< 120 g/L 2 (2.2) 7 (6.2)
≥ 120 g/L 88 (97.8) 106 (93.8)
Pretreatment KPS 0.697
< 80 6 (6.7) 5 (4.4)
≥ 80 84 (93.3) 108 (95.6)
Stage 0.146
IIIa 35 (38.9) 33 (29.2)
IIIb 55 (61.1) 80 (70.8)
Histology subtype 0.545
SCC 61 (67.8) 72 (63.7)
Non-SCC 29 (32.2) 41 (36.3)
Pretreatment CEA 0.729
< 5 ng/ml 50 (68.5) 62 (66.0)
≥ 5 ng/ml 23 (31.5) 32 (34.0)
PET scan staging
Yes 25 (27.8) 28 (24.8) 0.629
No 65 (72.2) 85 (75.2)
Radiotherapy technique 0.010
3D-CRT 26 (28.9) 16 (14.2)
IMRT 64 (71.1) 97 (85.8)
Radiotherapy dose 0.342
≥ 60 Gy 71 (78.9) 95 (84.1)
< 60 Gy 19 (21.1) 18 (15.9)
Concurrent chemotherapy 0.010
EP 36 (40.0) 63 (55.8)
PC 49 (54.4) 38 (33.6)
others 5 (5.6) 12 (10.6)
Response 0.559
CR + PR 72 (80.0) 94 (83.2)
SD 18 (20.0) 19 (16.8)
CCT consolidation chemotherapy, CEA carcinoembryonic antigen, KPS
Karnofsky performance status, PET positron emission tomography, SCC
squamous cell carcinoma
aSmoking index is the number of cigarettes smoked per day × the number
of cigarette-years
Liu et al. BMC Cancer  (2015) 15:715 Page 3 of 9
CCT was 3 and 101 (89.4 %) patients completed ≥2 cycles
of CCT.
As shown in Table 1, females (23 % vs. 7.8 %; p = 0.003),
patients aged < 60 years (72.6 % vs. 53.3 %; p = 0.005) with
a smoking index ≤ 400 (46 % vs. 31.1 %; p = 0.031) who re-
ceived IMRT (85.8 % vs. 71.1 %; p = 0.010) and concurrent
EP chemotherapy (55.8 % vs. 40 %; p = 0.010) were more
prevalent in the CCT group than in the non-CCT group.
The remaining listed clinical characteristics were compar-
able between the two groups.
Survival and prognostic factors
The median OS and 5-year OS for all patients were
24 months and 26.9 %, respectively. Patients in the CCT
group achieved significant survival prolongation com-
pared with those in the non-CCT group (median OS,
27 months vs. 16 months; 5-year OS, 30.4 % vs. 22.5 %;
p = 0.012; Fig. 1a). The median CSS and 5-year CSS for
the CCT group (28 months and 34.4 %) in our study were
also superior to those for the non-CCT group (17 months
and 27.9 %) (p = 0.022), which was consistent with the OS
results. The median PFS and 5-year PFS were 12 months
and 21.8 % in the CCT group and 9 months and 21.4 % in
the non-CCT group, respectively (p = 0.291; Fig. 1b). The
5-year LRPFS were 37.3 % in the CCT group and 35.1 %
in the non-CCT group (p = 0.265; Fig. 1c). The 5-year
DMFS were 40.1 % in the CCT group and 42.2 % in the
non-CCT group (p = 0.779; Fig. 1d).
The results of the univariate and multivariate analyses
of potential prognostic factors for OS are shown in Table 2.
Univariate analysis identified the radiotherapy dose <
60 Gy (p = 0.014), no CCT (p = 0.012) and SD (p = 0.035)
as significant unfavorable prognostic factors. Multivariate
analysis identified pretreatment CEA ≥ 5 ng/ml (p =
0.047), no CCT delivery (p = 0.008), and SD (p = 0.036) as
predictors for poor OS. Additional file 1: Table S1 shows
the results of the univariate and multivariate analyses of
potential prognostic factors for PFS. The univariate ana-
lysis showed superior PFS for patients with SCC histology
(p = 0.013), normal pretreatment CEA (p = 0.000), radio-
therapy dose ≥ 60 Gy (p = 0.019) and CR or PR (p = 0.049).
In the multivariate analysis, age < 60 years (p = 0.012),
pretreatment CEA ≥ 5 ng/ml (p = 0.000), and no CCT
delivery (p = 0.022) were significantly associated with
unfavorable PFS.
In the subgroup analysis, the median OS and 5-year
OS for patients receiving ≥2 cycles of CCT (27 months
and 31.8 %) were better than those administered with
<2 cycles of CCT (22 months and 18.7 %) (p = 0.317).
The median time interval between completion of CRT
to CCT was 6 weeks. The median OS and 5-year OS for
patients with intervals ≤ 6 weeks (28 months and 34.4 %)
were not statistically different from those with inter-
vals > 6 weeks (25 months and 24 %) (p = 0.281). A forest
plot of HRs for OS stratified by study characteristics is
shown in Fig. 2. The survival advantages of CCT were
statistically significant for males (HR: 0.63; 95 % CI, 0.44–
0.90; p = 0.011), patients with age < 60 years (HR: 0.63;
95 % CI, 0.42–0.95; p = 0.027), non-squamous histology
(HR: 0.44; 95 % CI, 0.25–0.76; p = 0.003), pretreatment
KPS ≥ 80 (HR: 0.67; 95 % CI, 0.48–0.93; p = 0.017), stage
IIIb (HR: 0.64; 95 % CI, 0.43–0.95; p = 0.025), SD (HR:
0.31; 95 % CI, 0.14–0.65; p = 0.002) and radiotherapy
dose ≥ 60 Gy (HR: 0.69; 95 % CI, 0.48 − 1.00; p = 0.048).
Toxicity
The treatment-related acute toxicities during the CRT
and the CCT phase are listed in Table 3. The inci-
dence of grade ≥ 3 hematological toxicities between
the CCT group and the non-CCT group was similar
(30.1 % vs. 34.4 %; p = 0.509) during the CRT phase.
In patients receiving CCT, 15 % experienced grade ≥ 3
hematological toxicities during the CCT phase and no
patient had grade 5 hematological toxicities. The inci-
dence of grade ≥ 3 esophagitis was comparable be-
tween the CCT group and the non-CCT group during
the CRT phase (9.7 % vs. 13.3 %; p = 0.422). Grade ≥ 3
radiation pneumonitis occurred at similar rates be-
tween the CCT and the non-CCT group during the
CRT (0.0 % vs. 2.2 %; p = 0.195) and CCT phase
(5.3 % vs. 3.3 %; p = 0.737). A total of 4 patients died of
grade 5 radiation pneumonitis, including 2 (2.2 %) in the
CCT group and 2 in the non-CCT (1.8 %) group.
Discussion
The outcomes of LA-NSCLC are relatively poor, with a
high possibility of residual disease after definitive CRT.
Thus, many clinical trials have investigated the role of
additional CCT. To date, three randomized phase III
studies [6, 9, 10] have been carried out to explore the
efficacy and toxicity of CCT, among which only one has
been published as a full article. HOG [6] reported that
consolidation docetaxel yielded no survival benefit (me-
dian OS, 21.2 months vs. 23.2 months; p = 0.883) with
an increased risk for grade 3/4 pneumonitis (9.6 % vs.
1.4 %; p < 0.001), infections (11 % vs. 0 %; p = 0.003),
hospitalization (28.8 % vs. 8.1 %) and treatment-related
death (5.5 % vs. 0 %; p = 0.058). In the GILT [9] study,
consolidation oral vinorelbine (NVBo) and cisplatin (P)
after NVBo plus P failed to prolong the median PFS
(6.4 months vs. 5.5 months; p = 0.630) and 4-year OS
(25.3 % vs. 21.4 %). The multinational CCheIN trial [10]
reported that consolidation DP (docetaxel plus cisplatin)
after concurrent weekly DP resulted in a PFS (median
PFS, 9.1 months vs. 8.1 months; p = 0.390) and a OS
(median OS, 21.8 months vs. 20.6 months; p = 0.490)
that were similar to those of the observation group. A
recently reported pooled-analysis including forty-one
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phase II/III studies with 3479 patients also failed to pro-
vide significant survival benefit of CCT for LA-NSCLC.
Unlike HOG, the GILT study and CCheIN trial observed
that the addition of CCT did not increase the toxicities.
Despite the negative results mentioned above, many on-
cologists still attempt to deliver CCT for LA-NSCLC pa-
tients with good performance status after CRT in routine
clinical practice, at least partially due to a poor survival
rate of less than 20 % at 5 years and a significant survival
benefit achieved by CCT in stage IV disease.
The long-term results of this retrospective study sug-
gest that CCT further prolongs survival compared with
CRT alone for LA-NSCLC without increased toxicities.
Although more patients in the CCT group had a positive
selection factors (female, younger age and a lighter his-
tory of smoking), the multivariate analysis was able to
account for those selection bias and showed that CCT
was a positive prognostic factor for OS and PFS. For pa-
tients in the CCT group, the encouraging median OS
and 5-year OS were 27 months and 30.4 %, respectively,
which were superior to those reported in randomized
clinical trials [6, 9, 10] and comparable to the survival
results in SWOG 9504. The median OS and 5-year OS
were 16 months and 22.5 %, respectively, in the non-
CCT group, which were similar to the historical controls
[4, 7]. Although there was no difference regarding LRPFS
or DMFS between the CCT group and the non-CCT
group, CCT prolonged survival compared with CRTalone,
which may be attributed to several reasons as follows.
First, the multivariate analysis for PFS showed that CCT
was an independent favorable prognostic factor (HR =
0.643; 95 % CI, 0.441–0.937; p = 0.022), though we found
that the LRPFS (p = 0.265) and DMFS (p = 0.779) out-
comes were similar between the CCT and non-CCT
group. The improvement in disease control may translate
into improved survival. The improvement in disease con-
trol may translate into improved survival. The multivariate
analysis for PFS showed that CCT was an independent
favorable prognostic factor (HR = 0.643; 95 % CI, 0.441–
0.937; p = 0.022). A second explanation is that ethnicity
may affect the efficacy of CCT. Our result is consistent
with a recent pooled analysis [2] that suggested that sur-
vival was better in Asian patients when CCT was deliv-
ered, though this improvement was not statistically
significant. Soo et al.[11] reported that the survival and re-
sponse rate to chemotherapy were better in Asian patients
with lung cancer, while the treatment-related toxicities
were more severe than in Caucasian patients. To date, the
exact mechanisms with which ethnicity affects the efficacy
of CCT are unknown. The interethnic difference may be
attributable to differences in the genetic backgrounds or
environment and culture. Third, it should be noted that
the actually delivered cycles of CCT in most studies
were relatively lower (0.7 to 3.1, average: 1.5) than
those observed in our study (the median number was
3 and 89.4 % of patients completed ≥2 cycles of CCT).
Fig. 1 Comparison of a overall survival (OS), b progression-free survival (PFS), c local regional progression-free survival (LRPFS) and d distant
metastasis-free survival (DMFS) between the consolidation chemotherapy (CCT) and non-CCT groups
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Table 2 Results of the univariate and multivariate analyses of prognostic factors for OS
Univariate analysis Multivariate analysis





< 60 years 24 26.5
≥ 60 years 21 27.6
Weight loss 0.292 1.01 0.61–1.66 0.977
< 5 % 24 28.7
≥ 5 % 24 20.2
Smoking index 0.399
≤ 400 26 26.5
> 400 20 27.4
Pretreatment hemoglobin 0.580
< 120 g/L 35 -
≥ 120 g/L 24 26.8
Pretreatment KPS 0.096 0.68 0.34–1.37 0.285
< 80 16 9.1







Pretreatment CEA 0.076 0.67 0.45–0.99 0.047
< 5 ng/ml 27 30.9
≥ 5 ng/ml 23 18.3
Radiotherapy technique 0.128 1.09 0.66–1.79 0.743
3D-CRT 18 16.2
IMRT 25 30.1
Radiotherapy dose 0.014 0.66 0.42–1.04 0.071
≥ 60 Gy 25 29.5
< 60 Gy 19 14.9
Concurrent chemotherapy
EP 27 29.8 0.365
PC 19 24.0
Others 25 -
Treatment modality .012 0.61 0.42–0.88 0.008
CRT + CCT 27 30.4
CRT 16 22.5
Response 0.035 0.62 0.40–0.97 0.036
CR + PR 24 29.7
SD 21 10.6
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Last, bias may be involved in such a retrospective study.
The choice of oncologists and patients may influence the
administration of CCT. Treatment compliance was higher
in patients in the CCT group than in those in the non-
CCT group because some patients refused CCT despite
the oncologists’ suggestion. Treatment compliance could
impact patients’ routine follow up and motivation for sal-
vage treatment after progression, which influences the
outcome. The reason why CCT resulted in no significant
increase in toxicities may be increased use of IMRT
(85.8 % vs. 71.1 %; p = 0.010) and timely management of
toxicity, as IMRT may decrease esophageal and pulmon-
ary toxicity compared with 3D-CRT by increasing target
conformity [12, 13].
Our study also suggested that CCT may lead to
significant OS benefit for males, patients with age <
60 years, non-squamous histology, pretreatment KPS ≥
80, stage IIIb, SD and radiotherapy dose ≥ 60 Gy. It
seems plausible that fit patients with higher risk of
distant metastasis would benefit from CCT. Interest-
ingly, the fact that the HR for patients achieving SD
is favoring CCT, which is contrary to Jeremic [14]
Fig. 2 Hazard ratios of CCT to non-CCT in subgroup analysis according to study characteristics
Table 3 Treatment-related toxicities
Toxicity CRT phase CCT phase
CCT (%) Non-CCT (%) Total p-value CCT (%) Non-CCT (%) Total p-value
Hematological 0.509 -
Grade 3/4 34 (30.1) 31 (34.4) 65 (32.0) 17 (15.0) - -
Grade 1/2 79 (69.9) 59 (65.6) 138 (68.0) 96 (85.0) - -
Esophagitis 0.422 -
Grade 3 11 (9.7) 12 (13.3) 23 (11.3) - - -
Grade 1/2 102 (90.3) 78 (86.7) 180 (88.7) - - -
Radiation pneumonitis 0.195
Grade≥ 3 0 (0.0) 2 (2.2) 2 (1.0) 6 (5.3) 3 (3.3) 9 (4.4) 0.737
Grade 1/2 113 (100.0) 88 (97.8) 201 (99.0) 107 (94.7) 87 (96.7) 194 (95.6)
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holding the view that patients with a CR or a PR rather
than those with a SD were likely to benefit from CCT.
However, the number of patients with SD in our study
was too small to draw a conclusion.
Prognostic factors are essential to understand the dis-
ease process, select treatments and design clinical trials.
Numerous studies have investigated the prognostic fac-
tors for LA-NSCLC with inconsistent results. The com-
monly recognized favorable prognostic factors include
stage IIIa, good performance status, non-significant
weight loss, and female gender [15–17]. In our study,
the multivariate analyses identified pretreatment CEA ≥
5 ng/ml, no CCT, and SD after CRT as predictive of
worse OS. Age < 60 years, pretreatment CEA ≥ 5 ng/ml,
and no CCT were significantly associated with poor PFS.
Our study did not show a significant association be-
tween OS or PFS and the widely recognized prognostic
factors mentioned above, which may be the result of a
relatively small sample size and under-representation of
patients with pretreatment KPS < 80 (5.4 %) and weight
loss ≥ 5 % (18 %).
Similar to our results, a retrospective study [18] re-
ported that the clinical tumor response was significantly
associated with OS. Kim et al. [19] found a five-fold like-
lihood of long term survival for responders (CR or PR)
compared to non-responders (SD or PD) (p = 0.067).
Because the clinical tumor response can be assessed
soon after CRT, this approach may aid in the following
treatment decision according to clinical tumor response
to initial CRT because non-responders may need more
aggressive treatment.
The prognostic role of age for LA-NSCLC is contradict-
ory. A Radiation Therapy Oncology Group (RTOG)-based
analysis [17] found that age ≤ 70 years was associated with
improved survival. Nevertheless, the secondary analysis of
RTOG 9410 [20] demonstrated that in patients treated
with CRT, the median OS was longer for patients aged ≥
70 years (22.4 months vs. 15.5 months, p-value not pro-
vided). Numerous recent trials [21–23] suggested that
CRT yielded similar treatment outcome for fit older pa-
tients compared with younger patients, which agreed with
our results that the elderly (age ≥ 60 years) were non-
inferior to the young (age < 60 years) with respect to OS.
The reason why age < 60 years acted as a negative pre-
dictor for PFS is unknown. The difference in the biological
behavior between younger and older patients warrants
further investigation.
Although our study is based on a relatively large sam-
ple size with a long follow-up period, it has some limi-
tations. Like all other retrospective studies, our study is
inevitably subject to multiple biases. Moreover, the
CCT regimens were largely heterogeneous, which hin-
dered our study from further exploring the most effect-
ive CCT regimen.
Conclusions
This retrospective study suggested that CCT further pro-
longed survival compared with CRT alone for LA-
NSCLC without increasing treatment-related toxicities.
Subgroup analysis identified that the survival advantages
of CCT were more significant for males, patients with
age < 60 years, non-squamous histology, pretreatment
KPS ≥ 80, stage IIIb, SD and radiotherapy dose ≥ 60 Gy.
Further prospective investigations that incorporate pa-
tient characteristics and treatment response are needed
to validate our results.
Additional file
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SD: Stable disease; SWOG: Southwest oncology group.
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